Fwd: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 May 27;
Shabo I, Stål O, Olsson H, Doré S, Svanvik J

Cells of the monocyte/macrophage lineage are important for tumour cell migration, invasion and metastasis. Fusion between macrophages and cancer cells in animal models in vitro and in vivo causes hybrids with increased metastatic potential. Primary breast cancer cells were characterized for macrophage antigens to test if phenotypic resemblance to macrophages is related to early distant recurrence. Immunostaining for CD163, MAC387 and CD68 was performed in a breast cancer tissue micro array from 127 patients consequently followed up for a median of 13 years. Tumour-associated macrophages expressed all 3 antigens. The breast cancers expressed CD163 to 48%, MAC387 to 14% while CD68 was not expressed. TGF-beta staining intensity was positively related to both CD163 and MAC387 expression. Expression of CD163 in the cancer cells was compared to their DNA ploidy, Nottingham Histological Grade, TNM-stage, node state, presence of estrogen receptors and occurrence of distant metastases and survival. Cancers of a more advanced histological grade expressed CD163 to a higher extent. Cells expressing MAC387 were more common in cancers with a high proportion of CD163 positive cells. Multivariate analysis showed that expression of the macrophage antigen CD163 in breast cancer cells has a prognostic impact on the occurrence of distant metastases and reduced patient survival time. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18506688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: K-State to host fund-raising event in Earl Woods' honor Saturday - Wichita Business Journal

---------- Forwarded message ----------
From: asbestos cancer - Live Search News <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:51 AM
Subject: K-State to host fund-raising event in Earl Woods' honor Saturday - Wichita Business Journal
To: mesothelioma77@gmail.com


Delicate Balance [Wichita] KSU's Leasure Hall closed amid concern over asbestos [Wichita] Former regent named chairman of K-State presidential search committee [Wichita] Harris gets $42M Army contract [Orlando] Eagle Group now part of Lockheed Martin ...

Thu, 29 May 2008 21:36:00 GMT

___
Source: http://wichita.bizjournals.com/wichita/stories/2008/05/26/daily23.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Radiographer gender and breast-screening uptake.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Radiographer gender and breast-screening uptake.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 3; 98(11): 1759-61
Fitzpatrick P, Winston A, Mooney T

BreastCheck, the Irish National Breast Screening Programme, screens women aged 50-64. Radiographer recruitment has been a challenge; doubling of numbers is required for full national expansion; to date females are employed. The aim was to document attitudes to male radiographers and effect on return for subsequent screening. In all 85.8% of a random sample of 2000 women recently screened by BreastCheck completed a postal questionnaire. The commonest reaction women felt they would have if there were a male radiographer was embarrassment; significantly greater among those attending a static unit (45.6%) than mobile (38.4%) and in younger women (46%) than older (38.7%). Nine per cent would not have proceeded if the radiographer was male and 9% would only have proceeded if female chaperone present. In all 17.5% (95% CI 15.7-19.4%) agreed that 'If there were male radiographers I would not return for another screening appointment'; 18.3% were unsure. One-quarter agreed 'if I heard there could be male radiographers it would change my opinion of BreastCheck for the worse'. The proportions agreeing with these statements did not vary significantly by screening unit type, age group, area of residence or insurance status. This is the largest published study to date of this important issue; the correct balance between equality and programme performance must be identified.



___
Source: http://www.hubmed.org/display.cgi?uids=18506178
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Risks and benefits of bisphosphonates.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Risks and benefits of bisphosphonates.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 3; 98(11): 1736-40
Coleman RE

Bone is the most common site for metastasis in cancer and is of particular clinical importance in breast and prostate cancers due to the prevalence of these diseases. Bone metastases result in considerable morbidity and complex demands on health care resources, affecting quality of life and independence over years rather than months. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma as well as a wide range of solid tumours affecting bone by 30-50%. Quite appropriately, these agents are increasingly used alongside anticancer treatments to prevent skeletal complications and relieve bone pain. The use of bisphosphonates in early cancer is also increasingly important to prevent the adverse effects of cancer treatments on bone health. These include ovarian suppression and the use of aromatase inhibitors in breast cancer patients and androgen deprivation therapy in those with prostate cancer. Bisphosphonate strategies, similar to those used to treat postmenopausal osteoporosis, have suggested that bisphosphonates are a safe and effective treatment for the prevention of treatment-induced bone loss. When compared to other cancer therapies, the frequency and severity of adverse events related to bisphosphonate therapy are generally mild and infrequent; thus, the benefits of treatment with any bisphosphonate almost always outweigh the risks. However, renal dysfunction may occasionally occur and over recent years, a new entity, bisphosphonate-associated osteonecrosis of the jaw (ONJ), has been described. The incidence, clinical importance and prevention strategies to minimise the impact of this problem on patients requiring bisphosphonates is discussed.



___
Source: http://www.hubmed.org/display.cgi?uids=18506174
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc